Nemaura Medical, Inc. · OTC:NMRD

Nemaura Medical — Technical Presentation (September 2018)

11 slides from Nemaura Medical's technical presentation, Sep 12, 2018

  1. Slide 1: Prospective Single Centre Evaluation of sugarBEAT CGM: Interim Evaluation

    A Prospective Single Centre Evaluation of the Accuracy and safety of the Nemaura Medical sugarBEAT® Non-invasive Continuous Glucose Monitor (CGM) System: An interim Evaluation Better Diagnostics for Life 12th September 2018 NASDAQ: NMRD Author Dr T Rahman, MBBS, PhD Clinical research Manager, Nemaur

  2. Slide 2: Study Objective

    Study Objective A EU-based study to determine the safety and accuracy of the sugarBEAT® CGM to support FDA submission 2

  3. Slide 3: Study Design

    Prospective single arm, single centre study Abbott Freestyle Optimum Neo BGM used as reference for Home Study Portion NEMAURA MEDICAL Accuracy and safety assessed over 7 consecutive Venous blood samples used as reference for in-clinic wear days, consisting of 3 non-consecutive in-clinic portion of s

  4. Slide 4: Study Methods

    Study Methods –– –– –– –– –– –– –– 4

  5. Slide 5: Baseline Characteristics

    Baseline Characteristics Variable Age - Range 27-67 years Age - Mean 52.8 years Age - Median 54.5 years Type 1 (n) 12 Type 2 (n) 13 5

  6. Slide 6: Accuracy vs Glucose Range In-clinic portion 1-point calibration

    Accuracy vs Glucose Range In-clinic portion of study 1-point calibration Glucose range Number of Within ±10% or Within ±15% or Within ±20% or Within ±30% or Within ±40% or Outside±40% (mg/dl) paired points ±10 mg/dl ±15 mg/dl ±20 mg/dl ±30 mg/dl ±40 mg/dl or ±40 mg/dl (MARD) (MARD) (MARD) (MARD) (MA

  7. Slide 7: Accuracy vs Glucose Range In-clinic portion 2-point Calibration

    Accuracy vs Glucose Range In-clinic portion of study 2-point Calibration Glucose range Number of Within ±10% or Within ±15% or Within ±20% or Within ±30% or Within ±40% or Outside±40% or (mg/dl) paired points ±10 mg/dl ±15 mg/dl ±20 mg/dl ±30 mg/dl ±40 mg/dl ±40 mg/dl (MARD) (MARD) (MARD) (MARD) (MA

  8. Slide 8: Interim Comparative MARD for In-Clinic phase

    Interim Comparative MARD for In-Clinic phase as Primary Accuracy Metric DexcomG5* no. of calibrations not known Overall MARD (20%/20mg/dL) 9.00 % Data 94.00 sugarBEAT 1-point calibration Overall MARD (20%/20mg/dL) 8.77 % Data 62.61 2-point calibration Overall MARD (20%/20mg/dL) 7.97 % Data 74.00 1-p

  9. Slide 9: Interim Comparative MARD for home-study phase

    Interim Comparative MARD for home-study phase as Primary Accuracy Metric Device No. of Subjects Paired Data Points with BGM Nominal MARD Reference BGM Senseonics Eversense* 23 829 14.80% Nova Biomedical StatStrip Xpress Dexcom G5* 23 829 16.30% Nova Biomedical StatStrip Xpress Abbott Libre Pro* 23 8

  10. Slide 10: Safety Evaluation

    Safety Evaluation Past Studies Current Studies –– –– –– 10

  11. Slide 11: Conclusions

    Conclusions The interim analysis indicates the 3 day in- clinic portion of the study shows accuracy levels, as measured using overall nominal MARD, as comparable to previously reported data and within the targets for the intended indications. 11

Nemaura Medical — Technical Presentation (September 2018) on 6ix